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Abstract Hemorrhagic cystitis often develops in patients
treated with cyclophosphamide (CYP). Studies have indi-
cated that Rho kinase (ROCK) inhibitors may suppress
detrusor overactivity symptoms and possess anti-
inflammatory properties. The aim of the present study
was to investigate whether inhibition of ROCK reduces
cystometric and histopathological changes associated with
CYP-induced cystitis. The rats received GSK 269962, a
ROCK inhibitor, at a dose of 30 mg/kg daily, or vehicle
for 7 days. Then, acute chemical cystitis leading to blad-
der overactivity was induced by CYP injection (200 mg/kg
i.p.). Following CYP injection, cystometric studies with
physiological saline were performed. Moreover, bladder
edema (by the Evans Blue dye leakage technique) and
urothelium thickness were measured. CYP injection re-
sulted in a significant increase in cystometric parameters:
basal pressure, threshold pressure, bladder contraction du-
ration, relaxation time, detrusor overactivity index, non-
voiding contractions amplitude, and non-voiding contrac-
tions frequency as well as increased Evans Blue extrava-
sation into bladder tissue, whereas micturition voiding
pressure, voided volume, post-void residual, volume
threshold, intercontraction interval, bladder compliance,
and volume threshold to elicit non-voiding contractions
as well as urothelium thickness were significantly de-
creased in CYP-injected rats. Administration of GSK
269962 normalized the abovementioned CYP injection-
induced changes. Inhibition of ROCK was found to ame-
liorate CYP-induced detrusor overactivity and bladder in-
flammation. Our data indicate uroprotective effects fol-
lowing ROCK inhibition, which further suggests that this
strategy may become an interesting pharmacological tool
to prevent urinary adverse effects in patients treated with
chemotherapy using CYP.
Keywords Cyclophosphamide-induced cystitis . Overactive
bladder . Bladder inflammation . Cystometry . Rho kinase
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Introduction
Hemorrhagic cystitis (HC) is a life-threatening condition de-
fined by lower urinary tract symptoms that include hematuria
and bladder detrusor overactivity. HC occurs in 10 to 40% of
patients receiving high-dose cyclophosphamide (CYP)
(Emadi et al. 2009; Watson and Notley 1973), which is one
of the most widely used chemotherapy drugs. The severity of
HC induced by CYP ranges from mild to severe and may
require a variety of procedures like hydration, clot extraction
via cystoscopy, continuous bladder irrigation, or cystectomy
(Matz and Hsieh 2017); however, despite those treatment op-
tions, can be fatal (Ebiloglu et al. 2016). Therefore, its
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prevention is a great challenge. Administration of a sulfhydryl
compound MESNA and hyperhydration are two most fre-
quently used methods for the prevention of HC in patients
treated with CYP, but they are not always effective and cannot
be used in all patient populations (Payne et al. 2013). Hence,
there is a need for novel agents that could be useful to prevent
adverse urologic effects during CYP therapy.
Increasing evidence suggests that Rho kinase (ROCK) is
an interesting target for the treatment of bladder overactivity.
ROCK belongs to the family of serine/threonine AGC (cyclic
AMP-dependent protein kinase A (PKA)/protein kinase G
(PKG)/protein kinase C (PKC)) kinases. Two major isoforms
ROCK1 and ROCK2 have been identified and both are
expressed in the urinary bladder (Wibberley et al. 2003).
ROCK phosphorylates substrates such as LIM kinase, myosin
light chain (MLC) phosphatase, and directlyMLC, thus, plays
a key role in smooth muscle contraction, including those of
the urinary bladder detrusor (Wróbel et al. 2008). As an effec-
tor protein of the small GTPase Rho, it is involved in the
mechanism of action of antimuscarinic drugs, which are ap-
proved for the treatment of overactive bladder (OAB) and
which clinical efficacy is driven by occupation at muscarinic
M3 receptors, since Rho protein can be activated followingM3
activation (Hegde 2006). Moreover, as ROCK inhibitors were
found to be active in several animal models of OAB, direct
inhibition of ROCK has been proposed as a novel strategy for
the treatment of OAB (Dimitropoulos and Gravas 2016).
In addition to its role in smooth muscle contraction, grow-
ing evidence indicates the involvement of ROCK in inflam-
matory processes (LoGrasso and Feng 2009). Studies on the
pathophysiology of CYP-induced HC have shown that it is a
non-microbial inflammation, initiated by the contact of CYP
liver metabolite, acrolein, with urothelium, in which proin-
flammatory cytokines (such as tumor necrosis factor-α
(TNF-α) and interleukin-1β (IL-1β)) and transcription factors
(such as nuclear factor kappa B (NF-κB)) participate (Dobrek
and Thor 2012; Korkmaz et al. 2007). One of the crucial
mechanisms of inflammatory events after acrolein enters the
uroepithelial cells is the effect on NF-κB (Korkmaz et al.
2007). ROCK can activate NF-κB (Segain et al. 2003); there-
fore, its inhibition seems to be a possible therapeutic strategy
for the treatment of CYP-induced HC.
We have previously demonstrated that acute treatment with
a ROCK inhibitor, GSK 269962, reversed acetic acid-induced
and ovariectomy-induced changes in cystometric parameters
(Wróbel and Rechberger 2015; Wróbel and Rechberger
2016a). Furthermore, a combined treatment of low, ineffective
doses of GSK 269962 and low, ineffective doses of
antimuscarinic drug, solifenacin, triggered a reversal of
ovariectomy-induced cystometric alterations (Wróbel and
Rechberger 2016a). Considering the potential influence of
ROCK inhibition on bladder overactivity and inflammatory
cascade, here, we tested whether GSK 269962 would rescue
cystometric and inflammatory changes in a model of cystitis
induced by CYP injection, which is widely used for investi-
gation of the pathophysiology, prevention, and treatment of
HC as well as a model for bladder inflammation and OAB
(Juszczak et al. 2010; Lee et al. 2014).
Materials and methods
Animals
All procedures were conducted in accordance with the
European Communities Council Directive of 22 September
2010 (2010/63/EU) and Polish legislation acts concerning an-
imal experimentations. The experimental procedures and pro-
tocols were approved by the First Local Ethics Committee at
the Medical University of Lublin. Sixty female Wistar rats
were used in the study and were randomly divided into four
groups of 15 animals each. Rats were placed individually in
metabolic cages (3700M071, Tecniplast, West Chester, PA,
USA) with free access to food and water. All experimental
procedures were carried out between 8 a.m. and 1 p.m.
All the surgical procedures were performed under anesthe-
sia with intraperitoneal (i.p.) injection of 75 mg/kg of keta-
mine hydrochloride (Ketanest, Pfizer) and 15 mg/kg of
xylazine (Sedazin, Biowet, Puławy, Poland). It was reported
that ketamine in combination with xylazine does not abolish





orpholinyl)ethoxy]benzamide, Tocris), a potent ROCK in-
hibitor (IC50 values: 1.6 and 4 nM for ROCK1 and
ROCK2, respectively) was dissolved in DMSO and adminis-
tered intravenously (i.v.) at a daily dose of 30 mg/kg. CYP
(Endoxan, Baxter Deutschland GmbH, Unterschleißheim,
Germany) was diluted with saline (0.9% NaCl) and adminis-
tered i.p. at a single dose of 200 mg/kg. The control rats
received volume-matched saline i.p. The doses of the admin-
istered agents were chosen based on the literature data and
were confirmed/adjusted in our laboratory in preliminary ex-
periments (Hidalgo-Lucas et al. 2016; Juszczak et al. 2010;
Kobayashi et al. 2009; Wróbel and Rechberger 2015; Wróbel
and Rechberger 2016a; Wróbel and Rechberger 2016b;
Wróbel and Rechberger 2016c).
Study design
The rats received GSK 269962 or vehicle for 7 days. On day
7, 1 h after the last injection of GSK 269962, the animals
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received CYP or a corresponding volume of saline. On day 8,
the surgical procedures were performed. On day 9, 48 h after
CYP injection, cystometric studies with physiological saline
were performed in conscious unrestrained rats. Following
cystometric studies, bladder edema and urothelium thickness
were measured.
Surgical procedures
The surgical procedures have been previously described in
detail (Wróbel et al. 2015). In brief, the abdominal wall was
opened through an approximately 10-mm vertical midline in-
cision. A double lumen catheter was inserted through the apex
of the bladder dome and fixed with 6–0 suture. The inner and
outer diameters of the catheter were 0.28 and 0.61 mm, re-
spectively. In the same session, the right femoral vein was
catheterised through an inguinal approach. The catheters were
tunneled subcutaneously (s.c.) and exteriorized in the
retroscapular area, where they were connected with a plastic
adapter, to avoid the risk of removal by the animal. The abdo-
men was closed in multiple layers. Anatomic layers were
closed using 4/0 catgut sutures. The free ends of catheters
were sealed with silk ligatures. The animals were injected
s.c. with 100 mg of cefazolin sodium hydrate (Biofazolin,
Sandoz, Holzkirchen, Germany) to prevent urinary tract
infection.
Conscious cystometry
Cystometric investigations were performed in conscious un-
restrained rats 1 day after surgical procedures. The bladder
catheter was connected via a three-way stopcock to a pressure
transducer (FT03, Grass Technologies, West Warwick, RI,
USA) and to a microinjection pump (CMA 100, CMA
Microdialysis AB, Kista, Sweden). Conscious cystometry
was performed by slowly filling the bladder with physiologi-
cal saline at a constant rate 0.05 ml/min to elicit repetitive
voiding. Micturition volumes were measured by means of a
fluid collector attached to a force displacement transducer
(FT03C). Both transducers were connected to a polygraph (7
DAG, Grass Technologies, West Warwick, RI, USA).
Cystometry profiles and micturition volumes were recorded
continuously on a Grass polygraph (Model 7E, Grass
Technologies, West Warwick, RI, USA) and were determined
graphically. The data were analyzed using a sampling rate of
10 samples. The measurements in each animal represent the
average of five bladder micturition cycles after obtaining re-
petitive voiding.
The following cystometric parameters were recorded: basal
pressure (BP, cm H2O), threshold pressure (TP, cm H2O),
micturition voiding pressure (MVP, cm H2O), voided volume
(VV, ml), post-void residual (PVR, ml), volume threshold
(VT, ml), voiding efficiency (VE, %), intercontraction interval
(ICI, s), bladder contraction duration (BCD, s), relaxation time
(RT, s), bladder compliance (BC, ml/cm H2O), detrusor over-
activity index (DOI, cm H2O/ml), non-voiding contractions
amplitude (ANVC, cm H2O), non-voiding contractions fre-
quency (FNVC, times/filling phase), and volume threshold
to elicit NVC (VTNVC, %).
Bladder edema measurement
Bladder edema was quantified by the determination of vesical
vascular permeability, which was measured by the Evans Blue
dye leakage technique. Evans Blue at a dose of 50 mg/kg was
injected i.v. via a polyethylene catheter inserted into the right
femoral vein 30 min before the animals were sacrificed. The
bladders were excised, weighted, sliced longitudinally, and
placed in 1 ml of formamide solution at 56 °C for 24 h.
Formamide absorbance was measured at 620 nM and was
compared to the standard curve. The results are presented as
nanogram of Evans Blue per milligram of the bladder.
Urothelium thickness measurement
The image analyzer computer system Leica Qwin 500 Image
Analyzer (Leica Imaging Systems Ltd., Cambridge, England)
was used to evaluate the urothelium thickness in micrometer
using the interactive measure menu and hematoxylin and
eosin-stained sections. A mean of 15 readings was estimated
from five serial sections from slides of each animal in each
group using low magnification (×10).
Statistical analysis
The obtained data were assessed by the one-way analysis of
variance (ANOVA) followed by Tukey’s post hoc test
(Statistica, v. 10, StatSoft, Inc., Tulsa, OK, USA). All results
are presented as the means ± standard error of the mean
(SEM). p < 0.05 was considered as a statistically significant
difference.
Results
The effects of pre-treatment with GSK 269962
on CYP-induced changes in cystometric parameters
One-way ANOVA demonstrated significant changes in
cystometric parameters: BP (F(3,59) = 12.96, p < 0.0001),
TP (F(3,56) = 86.85, p < 0.0001), MVP (F(3,56) = 13.83,
p < 0.0001), VV (F(3,56) = 21.31, p < 0.0001), PVR
(F(3,56) = 14.64, p < 0.0001), VT (F(3,56) = 5.645,
p = 0.0019), ICI (F(3,56) = 66.39, p < 0.0001), BCD
(F(3,56) = 21.13, p < 0.0001), RT (F(3,56) = 26.05,
p < 0.0001), BC (F(3,56) = 39.59, p < 0.0001), DOI
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(F(3,56) = 31.10, p < 0.0001), ANVC (F(3,56) = 53.20,
p < 0.0001), FNVC (F(3,56) = 132.4, p < 0.0001), VTNVC
(F(3,56) = 42.12, p < 0.0001) between the examined groups,
whereas VE parameter did not differ significantly between the
examined groups. The following parameters were significant-
ly increased in CYP-injected rats: BP, TP, BCD, RT, DOI,
ANVC, FNVC, whereas MVP, VV, PVR, VT, ICI, BC,
VTNVC parameters were significantly decreased in those rats,
compared to control animals. Administration of GSK 269962
to animals that received saline instead of CYP did not signif-
icantly affect the values of the cystometric parameters, com-
pared to control rats. Administration of GSK 269962 to ani-
mals that received CYP induced significant differences in the
parameters: BP, TP, MVP, VV, PVR, VT, ICI, BCD, RT, BC,
DOI, ANVC, FNVC, and VTNVC, compared to CYP group.
Administration of GSK 269962 to animals that received CYP
induced also significant differences in the parameters: ICI, RT,
BC, DOI, ANVC, FNVC and VTNVC, compared to GSK
269962 group (Table 1).
The effects of pre-treatment with GSK 269962
on CYP-induced changes in Evans Blue extravasation
and urothelium thickness
One-way ANOVA demonstrated significant changes in Evans
Blue extravasation into bladder tissue (F(3,56) = 152.9,
p < 0.0001) (Fig. 1a) and urothel ium thickness
(F(3,56) = 38.53, p < 0.0001) (Fig. 1b). CYP injection signif-
icantly increased Evans Blue extravasation and decreased
urothelium thickness in rats, compared to control animals.
Administration of GSK 269962 to animals that received saline
instead of CYP did not significantly affect Evans Blue extrav-
asation or urothelium thickness, compared to control rats.
Administration of GSK 269962 to animals that received
CYP significantly decreased Evans Blue extravasation and
increased urothelium thickness, compared to CYP group,
but did not affect these parameters compared to GSK
269962 group (Fig. 1a, b).
Discussion
Chemotherapy with oxazaphosphorines, such as CYP, is
often limited by urotoxicity, of which HC is a potentially
life-threatening condition. As HC may require inpatient
management and major procedures, which are not always
effective (Payne et al. 2013), its prevention is preferred
over treatment. Because CYP-induced HC is an inflam-
matory process (Korkmaz et al. 2007), compounds that
possess anti-inflammatory properties seem worth taking
into account while searching for agents that could be ben-
eficial for reducing adverse effects during CYP therapy.
Here, we found that ROCK inhibitor, GSK 269962,
ameliorated changes: increased plasma protein extravasa-
tion and decreased urothelium thickness, which were ob-
served after CYP injection. Our study shows anti-
inflammatory activity of GSK 269962 in the model of
acute, chemical, CYP-induced cystitis.
Other ROCK inhibitor, hydroxyfasudil, was found to ex-
ert anti-inflammatory effect in the model of HCl-induced
chemical cystitis (Shimizu et al. 2013). Hydroxyfasudil re-
duced the severity of histological changes associated with
HCl administration, such as epithelial denudation, submuco-
sal edema, inflammatory cell infiltrate, tissue granulation,
and vasodilation (Shimizu et al. 2013). Moreover,
hydroxyfasudil was shown to exhibit anti-inflammatory
properties in the model of protamine sulfate-induced cystitis,
as demonstrated by histopathological assessment (Akin et al.
2015). Thus, our and other findings support the role of
ROCK inhibition in reducing inflammation of the urinary
bladder.
Data have indicated the involvement of ROCK in the path-
ophysiology of bladder dysfunction. ROCK expression at the
gene and protein level as well as its activity were increased in
bladder smooth muscle of hepatic-specific insulin receptor
substrate 1 and 2 double knockout mice, which develop type
2 diabetes and bladder dysfunction; furthermore, ROCK ex-
pression and activity correlated with hyper- and hypoactivity
states of the bladder (Wang et al. 2012). Expression of
ROCK1 and ROCK2 at the mRNA level was also increased
in the bladder of rats in the model of HCl-induced cystitis
(Shimizu et al. 2013).
In the present study, we found that GSK 269962 amelio-
rated CYP injection-induced changes in all examined
cystometric parameters. We have previously shown that acute
treatment with GSK 269962 normalized acetic acid-induced
and ovariectomy-induced cystometric changes (Wróbel and
Rechberger 2015; Wróbel and Rechberger 2016a).
Furthermore, a combined treatment of low doses of GSK
269962 and low doses of antimuscarinic drug, solifenacin,
both ineffective as monotherapies, triggered a reversal in
cystometric alterations caused by ovariectomy (Wróbel and
Rechberger 2016a). Hydroxyfasudil was also shown to ame-
liorate CYP injection-induced detrusor overactivity (Masago
et al. 2009). Considering the effects of ROCK inhibition on
cystometric parameters as well as the involvement of ROCK
in the pathophysiology of bladder dysfunction, our data fur-
ther support the hypothesis that inhibition of this kinase might
be a new therapeutic strategy for bladder overactivity.
Uroprotective agent currently used in patients undergoing
CYP therapy, namely MESNA, is administered in divided
doses—prior and after CYP administration. This treatment
schedule highlights the need for administration of
uroprotective agent prior to CYP, what influenced our study
design. We focused on pre-treatment with GSK 269962 and





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































acid-induced and ovariectomy-induced-detrusor overactivity
(Wróbel and Rechberger 2015; Wróbel and Rechberger
2016a).
It has been proposed that CYP-induced HC is initiated
by direct contact of its metabolite, acrolein, with
urothelium, which causes edema, ulceration, neovascular-
ization, hemorrhage, and necrosis (Lee et al. 2014). One
of the most important mechanisms of inflammatory events
after acrolein enters into the uroepithelial cells is the ef-
fect on NF-κB. (Korkmaz et al. 2007). ROCK is one of
the factors activating NF-κB, while its blockade was
found to prevent inflammation via NF-κB inhibition
(Segain et al. 2003). Thus, beneficial effects of GSK
269962 in ameliorating inflammation might result from
inhibition of NF-κB.
Other pivotal mediators of inflammatory reaction in-
duced by CYP are proinflammatory cytokines: TNF-α
and IL-1β. It was shown that pre-treatment with anti-
TNF-α or anti-IL-1β serum diminished mucosal erosion,
hemorrhage, edema, leukocyte migration, and ulceration
in CYP-injected mice (Gomes et al. 1995). GSK 269962
was found to suppress generat ion of TNF-α in
lipopolysaccharide-stimulated monocytes (Doe et al.
2007). Other ROCK inhibitor, Y27632, was found to
block the increase in TNF-α and IL-1β release upon li-
popolysaccharide injection in vivo (Wang et al. 2012).
Therefore, the possible mechanism by which GSK
269962 diminished CYP-induced inflammation may be
associated with inhibition of TNF-α and/or IL-1β. It
should be noted that TNF-α and IL-1β activate NF-κB
through degradation of an inhibitory protein to which
NF-κB is connected in the cytoplasm. This allows
NF-κB enter the nucleus and subsequently promote tran-
scription of genes for proinflammatory cytokines, such as
TNF-α and IL-1β (Karin and Ben-Neriah 2000; Lawrence
2009). Thus, the possible inhibition of TNF-α and/or IL-
1β by GSK 269962 could also lead to inhibition of
NF-κB.
Another potential mechanism of beneficial effects of
ROCK inhibition on inflammatory changes in CYP-
induced cystitis may be due to the role of ROCK in leuko-
cyte extravasation. Migration of leukocytes across the endo-
thelial layer is a hallmark of inflammation. Activation of a
ROCK–MLC kinase pathway stimulates endothelial,
actomyosin-based contractility, whereas inhibition of this
pathway reduces leukocytes transendothelial migration
(Hordijk 2016). However, direct mechanisms by which
GSK 269962 exerts anti-inflammatory effect in a model of
CYP-induced cystitis need further examination.
Conclusions
Considering the effects of GSK 269962 on inflammatory
and cystometric parameters, inhibition of ROCK may be a
new pharmacological option for the treatment of bladder
inflammation and detrusor overactivity. Because GSK
269962 ameliorated CYP-induced bladder inflammation
and overactivity, our data indicate uroprotective effects
following ROCK inhibition, which further suggests that
this strategy may become a pharmacological tool to pre-
vent urinary adverse effects in patients treated with che-
motherapy using CYP. ROCK inhibitors may represent a
novel class of uroprotective agents, targeting inflammato-
ry basis of HC, i.e., pathogenesis-based, which beneficial
role in preventing/reducing CYP-induced HC may, at least
partly, result from anti-inflammatory properties.
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